Imagine a World Without Alcohol and Drug Addiction

What we do ?

DemeRx is a clinical stage drug development company advancing a new chemical entity for the treatment of alcohol use disorder

Noribogaine is a new molecule with robust patents for multiple therapeutic indications. Our current focus is for relapse prevention in alcohol use disorder.

Alcohol abuse has grave consequences on our society

The misuse of alcohol disrupts families, shreds social fabric, often leads to job and income loss, contributes to poor school and work performance, and is often a causal factor in domestic violence and auto accidents. The consequences of alcohol abuse for children in society are especially tragic. 

Addiction is a family disease.

Effective Solutions

Solutions in Development

Preventing relapse and easing protracted alcohol withdrawal symptoms for people in early recovery

 

DemeRx is advancing clinical trials to demonstrate that a daily dose of noribogaine can mitigate the complicated and unpleasant symptoms of withdrawal and cravings, making recovery more achievable.

Noribogaine (DMX-1001)

A new molecule in the class of neuroplastogens and a lead molecule for next generation drug products.

Potential opportunity to treat alcoholism and other addictive disorders.

Targets multiple transporter and receptor sites in brain relevant to craving, mood and protracted withdrawal symptoms that
trigger relapse.

Reduces self-administration of alcohol, opioids, cocaine and nicotine in rodent models of addiction.

 Treatment of alcohol use disorder in early abstinence is needed to prevent relapse. Medication development for the treatment of alcohol use disorder is an unmet need.

DemeRx's solution to alcoholism

DemeRx is evaluating the safety and pharmacokinetics of noribogaine in normal healthy volunteers to advance studies in patients with alcohol use disorder.

Noribogaine for alcohol use disorder

DemeRx will announce topline results from a multiple ascending dose study in Q1 2025. Next steps in clinical development are regulatory approvals of clinical trials of noribogaine for relapse prevention in treating alcohol use disorder.

Potential Advantages of Noribogaine

  • Rapid acting, once a day dosing
  • Long lasting therapy
  • Low to no abuse liability
  • Treatment of the neurological effects of substance abuse

Product Candidate

Learn about the target product profile of Noribogaine.

Our Team

Neuroscientists, drug developers, clinician scientists, and industry veterans with a track record of successful product launch.

Learn more

Interested in more information?

Learn about our leading drug candidates to dominate the $1.3B alcohol addiction market growth in 2033.

Scientific Publications

Latest Publications and Articles

Subscribe for updates.

Get the latest news and events.